We have found that the chemokine CXCL9 is upregulated during the development of AP, and that antagonizing CXCR3 suppresses the bone destruction that typifies this disease by inhibiting various pro-inflammatory cytokines that are also involved in destruction of alveolar bone. This evidence concerns the gene CXCL9 and alkaline phosphatase measurement.